Imrestor
Pegbovigrastim
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Imrestor. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Imrestor.
For practical information about using Imrestor, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Imrestor
|
Agency product number |
EMEA/V/C/002763
|
Active substance |
Pegbovigrastim
|
International non-proprietary name (INN) or common name |
Pegbovigrastim
|
Species |
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QL03AA90
|
Publication details | |
---|---|
Marketing-authorisation holder |
Elanco GmbH
|
Revision |
3
|
Date of issue of marketing authorisation valid throughout the European Union |
09/12/2015
|
Contact address |
Heinz-Lohmann-Str. 4 |
Product information
30/09/2020 Imrestor - EMEA/V/C/002763 - R/0015
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Colony stimulating factors
-
Immunostimulants
-
Antineoplastic agents
Therapeutic indication
As an aid in a herd management programme, to reduce the risk of clinical mastitis in periparturient dairy cows and heifers during the 30 days following calving.